PharmaFocus Today – Page 85 – media

Haier Bio terminate the planning of absorption merger with Shanghai Laishi

On the evening of January 6, 2025, Qingdao Haier Biomedical Co., Ltd. (“Haier Bio”, 688139.SH) and Shanghai Laishi Blood Products Co., Ltd. (“Shanghai Laishi”, 002252.SZ) announced the termination of the planning for a major asset restructuring and the resumption of the company’s stock trading. They have decided to terminate the substantial asset restructuring plan for Haier Bio to absorb and merge with Shanghai Laishi. At the same time, both companies issued announcements regarding a proposal from the chairman to repurchase shares. Haier Bio’s share repurchase plan totals between 100 million to 200 million yuan, while Shanghai Laishi’s totals between 250 million to 500 million yuan. The stocks of both companies will resume trading at the opening on Tuesday, January 7, 2025. According to the announcements from both companies, to enhance investor confidence and based on strong confidence in the future development of Haier Bio and Shanghai Laishi, as well as ...
- Source: drugdu
- 239
- January 10, 2025
Pianzaihuang settled in the biopharmaceutical cluster in Daxing District, Beijing, with an industrial scale of 73.7 billion yuan

The reporter learned from the “Two Sessions” in Daxing District that as the “main battlefield” for the development of Beijing’s biopharmaceutical industry, Daxing District will aggregate the biopharmaceutical ecosystem and achieve remarkable results in 2024. China Medicine Valley has been selected as a “Chinese characteristic biopharmaceutical industry park”, and the six centers directly under the National Medical Products Administration have been unveiled and put into operation. Capital Medical University has started construction, and 10 chain leading enterprises such as Pianzaihuang have flocked to accelerate the construction of a comprehensive biopharmaceutical cluster, with an industrial scale of 73.7 billion yuan. Recently, the neon lights of the Pien Tze Huang Beijing Innovation and Research Base building located in the Xingchuang International Center in Daxing District began to light up. It is reported that Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (hereinafter referred to as “Pien Tze Huang Company”) is steadily advancing its ...
- Source: drugdu
- 194
- January 9, 2025
Zhengye Biotechnology, the first US listed company in Jilin Province, has landed on NASDAQ

On the evening of January 7th Beijing time, Jilin Zhengye Biological Products Co., Ltd. (referred to as “Zhengye Biotechnology”) successfully went public on the NASDAQ Stock Exchange in the United States, filling the gap for Jilin Province’s enterprises to go public in the United States. Zhengye Biotechnology is an animal vaccine manufacturer whose main business includes research and development, manufacturing, sales, and technical services of animal vaccines. The company is located in Jilin City, Jilin Province, China. Its predecessor was Harbin Veterinary Biopharmaceutical Factory of the Ministry of Agriculture, which relocated to Jilin City in 1970. It is one of the earliest veterinary biopharmaceutical enterprises directly under the Ministry of Agriculture in China, with a history of more than 50 years. In 2004, Zhengye Biotechnology was restructured from Jilin Province Biological Products Factory and is now a privately-owned joint-stock enterprise. The company’s products cover four types of animal vaccines, including ...
- Source: drugdu
- 225
- January 9, 2025
Two medical devices have entered the priority approval channel

According to the China Medical Device Innovation and Priority Approval Database, in December 2024, two medical devices entered the priority approval green channel in public announcements issued by local drug regulatory authorities across the country. They are: the disposable electronic endoscopic thoracoscopic laparoscopic catheter from Fujian Zhide Medical Technology Co., Ltd. (hereinafter referred to as Fujian Zhide), and the cognitive impairment assisted diagnosis and rehabilitation software from Hainan Boya Health Technology Co., Ltd. (hereinafter referred to as Hainan Boya). Fujian Zhide: Focusing on Endoscopy Fujian Zhide was established in April 2022 and is a company dedicated to the research and manufacturing of electronic endoscopic medical devices. The disposable 4K electronic endoscope technology developed by the research and design team of Fujian Zhide Optics has received widespread attention. This technology is both safe and convenient, not only greatly reducing the infection rate and improving cost-effectiveness, but also adapting to grassroots needs. ...
- Source: drugdu
- 139
- January 9, 2025
Innovent has made a good start

At the beginning of the new year, Innovent Biologics brought the first good news of going overseas. Recently, Innovent Biologics and Roche reached a global exclusive cooperation and licensing agreement on the new generation of DLL3 antibody-drug conjugates. Innovent Biologics granted Roche the exclusive rights to the global development, production and commercialization of IBI3009. The two parties will jointly be responsible for the early development of the ADC candidate drug, and Roche will be responsible for subsequent clinical development. Innovent Biologics will receive a total transaction amount of US$1.08 billion (including an initial payment of US$80 million and potential development and commercialization milestone payments of up to US$1 billion, as well as sales commissions). Just a few days ago, Hengrui Medicine also reached a licensing cooperation for DLL3 ADC drugs. Hengrui Medicine licensed the overseas rights of SHR-4849 to IDEAYA Biosciences of the United States for a total amount of ...
- Source: drugdu
- 155
- January 9, 2025
A battle for survival for BTK inhibitors?

Recently, Sanofi’s Rilzabrutinib was applied for listing in China for the treatment of immune thrombocytopenia (ITP). This means that the “six-strong competition” pattern in the domestic BTK inhibitor market has begun to emerge. The autoimmune BTK inhibitor market is now a place of chaos. Before Sanofi’s Rilzabrutinib was applied for listing, five BTK inhibitors had been approved in China, including AbbVie/Johnson & Johnson’s ibrutinib, AstraZeneca’s acotinib, BeiGene’s zanubrutinib, Innovent’s obeticholic steroids, and Eli Lilly’s Pirtobrutinib. The indications are mainly concentrated in hematological tumors, and only a few have been approved for autoimmune diseases. It can be seen that focusing on autoimmune indications has become a differentiated breakthrough path. Sanofi’s Rilzabrutinib is the embodiment of this strategy. The strong players in the autoimmune track are not only AbbVie and Johnson & Johnson, but also Sanofi’s strength should not be underestimated. For example, the ace product Dupixent (dupixentumab) is a “super blockbuster” ...
- Source: drugdu
- 311
- January 9, 2025
WuXi Biologics Plans to Sell Irish Vaccine Facility-Related Assets for $500 Million

On January 6, WuXi Biologics announced that the company, along with its indirect wholly-owned subsidiary WuXi Biologics Ireland, has entered into an agreement with MSD International to sell assets related to its Irish vaccine facility for $500 million. WuXi Biologics stated that the net proceeds from the asset sale will be used for the group’s operational development and general working capital for various regional operations, as well as for potential further share buybacks by the company. WuXi Biologics primarily provides comprehensive end-to-end vaccine CDMO services and acts as a global biopharmaceutical CRDMO, offering end-to-end solutions for biopharmaceutical discovery, development, and production for clients in the biopharmaceutical industry. MSD International is a subsidiary of a global pharmaceutical company that provides innovative health solutions through its prescription medicines, vaccines, biologics, and animal health products. https://finance.eastmoney.com/a/202501073289649267.html
- Source: drugdu
- 113
- January 9, 2025
Poly Pharm Faces Potential Delisting After Two Years of Fabricated Financial Performance

On January 5, Poly Pharm announced that the company is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws and regulations. On January 4, the company received an “Advance Notice of Administrative Penalty” issued by the CSRC. According to the facts stated in the notice, the annual reports for 2021 and 2022 contain false records. Specifically, the fabricated operating revenue amounts to a total of 1.03 billion yuan, accounting for 31.08% of the total annual operating revenue disclosed for those two years. The total fabricated profit amounts to 695 million yuan, which constitutes 76.72% of the total annual profit disclosed for the same period. According to the facts established in the notice, Poly Pharm may engage in a significant violation that triggers mandatory delisting under the regulations of the “Shenzhen Stock Exchange’s Growth Enterprise Market Listing Rules (2024 revision),” which states that if ...
- Source: drugdu
- 218
- January 9, 2025
Sold for 4.5 billion! Why is another state-owned enterprise taking control of traditional Chinese medicine after selling medicine?

Accelerate the integration of state-owned assets and consolidate its leading position; Private traditional Chinese medicine enterprises are facing operational difficulties and are being rescued by state-owned assets; Industrial capital enters the market, promoting upstream and downstream collaboration. The triple logic, combined with policy effects, further promotes the inevitable trend of the integration of the traditional Chinese medicine industry to the waist and tail enterprises by 2025. In just two days since the beginning of 2025, two major events have already occurred: DLL3 has gone viral, and the new lung cancer star targets have attracted new trends; Shanghai Pharmaceuticals has locked in the exclusive large variety of traditional Chinese medicine, and plans to spend nearly 1 billion yuan to further integrate Hehuang Pharmaceuticals. With the state-owned “holding” of the traditional Chinese medicine industry, the value of once again has increased. On January 1st, Shanghai Pharmaceuticals announced its intention to jointly acquire ...
- Source: drugdu
- 170
- January 7, 2025
Did the new drug cost so much money and go to the wrong place?

The launch of new drugs seems to solve some clinical unmet problems, and theoretically, it seems to help improve the overall health of everyone. However, a recent paper published in The Lancet arrived at the opposite conclusion. They believe that over the past two decades, the funds used by the UK’s National Health Service (NHS) for newly approved drugs could actually bring more health benefits if they were instead invested in existing services. Investigation on NICE Database Researchers from the UK and the US first reviewed UK drug technology assessments published in the NICE (National Institute for Excellence in Healthcare Services) public database between 2000 and 2020. After investigating 183 drugs evaluated for 385 indications out of 339 evaluations in NICE’s new drug evaluation, they found that the median gain in quality adjusted life years (QALYs) was 0.49 throughout the entire evaluation, with moderate dispersion. Quality adjusted lifespan is an ...
- Source: drugdu
- 131
- January 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.